Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial

Atypical meningioma is a tumour that arises from the lining of the brain. It mostly affects adults, with most patients in the 40-60 year age group. The primary treatment for atypical meningioma is surgical removal, but with surgery alone up to 40% of patients will experience recurrence. Because of this risk, some clinicians give early radiotherapy, whilst others advise regular monitoring with radiotherapy given only at recurrence. Currently there is no consensus as to which of these two approaches is best. This randomised controlled trial will compare the two approaches, and aims to determine whether early radiotherapy reduces the risk of tumour recurrence compared to regular monitoring in newly diagnosed atypical meningioma.

Primary Sponsor

The Walton Centre NHS Foundation Trust, University of Liverpool, UK

Collaborating Groups

European Organisation for Research and Treatment of Cancer (EORTC) ; Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

15

Closing Date of Accrual

May 2021

Trial Chairperson

Dr Neda Haghighi, Peter MacCallum Cancer Centre, VIC

Trial Contact

ROAM@trog.com.au

Related Post

28 March, 2025

TROG Awards Recognise Research Excellence

Latest news: 28 March 2025. TROG Members who have

27 March, 2025

TROG 2025 ASM advances inclusivity and innovation

Latest news: 27 March 2025 With a theme of